Synairgen (GB:SNG) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Synairgen plc has announced the retirement of Chairman Simon Shaw and the appointment of Mark Parry-Billings as his successor after the upcoming AGM on October 10, 2024. Parry-Billings brings over 30 years of experience in biotech and pharmaceuticals, notably in respiratory therapeutics, to Synairgen, a company focused on developing SNG001, an inhaled antiviral treatment for severe viral lung infections.
For further insights into GB:SNG stock, check out TipRanks’ Stock Analysis page.